Moreover, Gal antagonists, such as LacNAc (N-acetyl-D-lactosamine) and TetraLacNAc (tetra-N-acetyl-D-lactosamine), reduce tumor growth by inducing IFN-gamma and chemokine production to induce CD8(+) T cell infiltration [145]. Here, CD8A is linked to neoplasm.